Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety‐five patients with R/R HL, who received BV in 20 centers from Greece, were an...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hematol Oncol
Autori principali: Angelopoulou, Maria K., Vassilakopoulos, Theodoros P., Batsis, Ioannis, Sakellari, Ioanna, Gkirkas, Konstantinos, Pappa, Vasiliki, Giannoulia, Panagiota, Apostolidis, Ioannis, Apostolopoulos, Christos, Roussou, Paraskevi, Panayiotidis, Panayiotis, Dimou, Maria, Kyrtsonis, Marie‐Christine, Palassopoulou, Maria, Vassilopoulos, Georgios, Moschogiannis, Maria, Kalpadakis, Christina, Margaritis, Dimitrios, Spyridonidis, Alexander, Michalis, Eurydiki, Anargyrou, Konstantinos, Repousis, Panagiotis, Hatzimichael, Eleutheria, Bousiou, Zoi, Poulakidas, Elias, Grentzelias, Dimitrios, Harhalakis, Nikolaos, Pangalis, Gerassimos A., Anagnostopoulos, Achilles, Tsirigotis, Panagiotis
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Original Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5836920/
https://ncbi.nlm.nih.gov/pubmed/28219112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hon.2383
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi